Paper Details

  1. Home
  2. Paper Details

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.

Author: FungSimon, ShirleyMatt

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Ripretinib is a drug that inhibits the growth of gastrointestinal stromal tumors (GISTs). It works by blocking the activity of KIT and PDGFRA, proteins that are often overactive in GISTs. Ripretinib has been shown to increase progression-free survival in patients with GISTs compared to placebo. The most common side effects of ripretinib are lipase increases, hypertension, fatigue, and hypophosphataemia.
Paper Details　
Original Abstract of the Article :
Ripretinib (Qinlock<sup>&#174;</sup>) is a small molecule inhibitor of the receptor tyrosine kinases KIT and platelet-derived growth factor receptor &#945; (PDGFRA) and is approved for the treatment of gastrointestinal stromal tumours as a fourth-line of therapy. After successive cycles of treatment...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40265-022-01794-0

データ提供：米国国立医学図書館（NLM）

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy

This review delves into the [oncology] field, focusing on the treatment of gastrointestinal stromal tumors (GISTs). The review examines the role of ripretinib, a novel tyrosine kinase inhibitor, in treating GISTs as a fourth-line or later-line therapy. Ripretinib has a dual mechanism of action that allows it to target a broad spectrum of mutations in KIT or PDGFRA, which are commonly found in GISTs. The review highlights the positive results of the pivotal phase III INVICTUS trial, which demonstrated an increase in progression-free survival in patients receiving ripretinib compared with placebo. The review concludes that ripretinib is a valuable addition to the treatment options for GISTs, offering hope for patients who have exhausted other treatment options.

New Hope for Gastrointestinal Stromal Tumors

This review provides a comprehensive overview of ripretinib's role in the treatment of GISTs. The drug's efficacy and acceptable tolerability make it a promising option for patients who have progressed on other therapies.

Understanding the Challenges of Cancer Treatment

This review underscores the challenges of treating advanced cancers. The development of resistance to conventional therapies highlights the need for new treatment approaches that target specific molecular pathways involved in cancer growth.

Dr.Camel's Conclusion

The journey through cancer treatment can be a long and arduous one. This review shines a light on a new treatment option, ripretinib, offering a potential oasis for patients with GISTs who have exhausted other therapies. This research highlights the importance of continued research and development of new treatments for cancer.
Date :
  1. Date Completed 2022-11-15
  2. Date Revised 2022-11-15
Further Info :

Pubmed ID

36282417

DOI: Digital Object Identifier

10.1007/s40265-022-01794-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.